Why Januvia is yet not Banned?

To avoid a shortage and help ensure patients have access to an adequate supply of the medicine, FDA will not object to the TEMPORARY distribution of sitagliptin containing NTTP above the acceptable intake limit of 37 ng per day, and up to 246.7 ng per day.

FDA also asked, The manufacturer of a marketed product that contains sitagliptin should contact the Center for Drug Evaluation and Research’s Drug Shortages Staff when its testing shows levels of NTTP that exceed 37 ng per day. FDA will determine on a case-by-case basis whether those drugs should be released for distribution.

The FDA noted that it could be dangerous for patients with type 2 diabetes mellitus to stop taking their sitagliptin without first talking to their health care professional. FDA recommends prescribers continue to use sitagliptin when clinically appropriate to prevent a gap in patient treatment.

NDMA is an environmental contaminant that can be found in water and foods and has been classified as a "probable human carcinogen" by the World Health Organization.

Are The Lawsuits Separate Or Class Action?

Each plaintiff's lawsuit will be separate. But to streamline litigation, all the lawsuits will be combined into an MDL (Multi-District Litigation).

In an MDL there is one judge who presides over every case during the pretrial stages. Then a few cases go to trial. The results of these bellwether trials are critical. They determine if there will be settlements, and for how much.

MDL's are different from class action lawsuits. In class actions, every member of the class gets the same settlement amount. In MDL's, each plaintiff gets a separate amount based on his/her own case.

Januvia Brands & Other Products containing Sitagliptin Phosphate